Canada Alzheimers Disease Diagnostics Market Size & Outlook
The alzheimers disease diagnostics market in Canada is expected to reach a projected revenue of US$ 871.0 million by 2033. A compound annual growth rate of 12.5% is expected of Canada alzheimers disease diagnostics market from 2026 to 2033.
In terms of revenue, Canada accounted for 3.7% of the global alzheimers disease diagnostics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. alzheimers disease diagnostics market is projected to lead the regional market in terms of revenue in 2033.
Canada is the fastest growing regional market in North America and is projected to reach USD 871.0 million by 2033.
A growing elderly population and advancements in diagnostic technologies are driving the market for Alzheimer's disease diagnostics in Canada. As the number of elderly individuals increases, the prevalence of neurodegenerative disorders, particularly Alzheimer’s disease, rises correspondingly.
Moreover, according to an article published by the Alzheimer Society of Canada in July 2024, researchers predict that about 1 million Canadians will have dementia by 2030. Additionally, they predict that by 2050, over 1.7 million Canadians will suffer from dementia.
Moreover, initiatives undertaken by key market players to strengthen their market position further contribute to market growth. For instance, in June 2023, Roche Diagnostics received Health Canada approval for its Cerebrospinal Fluid (CSF) assays designed to measure three biomarkers—betaamyloid and tau proteins—indicative of Alzheimer's pathology.
Canada Alzheimers Disease Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Alzheimers Disease Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Imaging Techniques was the largest segment with a revenue share of 45.11% in 2025.
Horizon Databook has segmented the Canada alzheimers disease diagnostics market based on biomarkers, imaging techniques, genetic testing, cognitive assessment tests covering the revenue growth of each sub-segment from 2021 to 2033.
A growing elderly population and advancements in diagnostic technologies are driving the market for Alzheimer's disease diagnostics in Canada. As the number of elderly individuals increases, the prevalence of neurodegenerative disorders, particularly Alzheimer’s disease, rises correspondingly.
Moreover, according to an article published by the Alzheimer Society of Canada in July 2024, researchers predict that about 1 million Canadians will have dementia by 2030. Additionally, they predict that by 2050, over 1.7 million Canadians will suffer from dementia.
Moreover, initiatives undertaken by key market players to strengthen their market position further contribute to market growth. For instance, in June 2023, Roche Diagnostics received Health Canada approval for its Cerebrospinal Fluid (CSF) assays designed to measure three biomarkers—betaamyloid and tau proteins—indicative of Alzheimer's pathology.
Canada Alzheimers Disease Diagnostics Market Diagnostic Technique Outlook (Revenue, USD Million , 2021-2033)
Biomarkers
Imaging Techniques
Genetic Testing
Cognitive Assessment Tests
Canada Alzheimers Disease Diagnostics Market Type Outlook (Revenue, USD Million , 2021-2033)
Triage
Diagnosis
Screening
Canada Alzheimers Disease Diagnostics Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals
Diagnostic Laboratories
Academic and Research Institutes
Reasons to subscribe to Alzheimers Disease Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Alzheimers Disease Diagnostics Market Outlook databook
Our clientele includes a mix of Alzheimers Disease Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada Alzheimers Disease Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Alzheimers Disease Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.